Figure 2 SCC mec typing among hVISA and MRSA isolates using Zhang’s method [32]. PVL genes Only one hVISA isolate and two MSSA isolates carried PVL. Furthermore, even the MRSA isolate with SCCmec type IVd did not carry the PVL gene. Agr-genotype All agr types were represented in the 24 isolates of hVISA (Figure 3): 37.5% were agr-group I,
see more 50.0% agr-group II, 8.4% agr-group III and 4.1% were non-typable. The 16 isolates of MRSA carried agr-group I (18.8%) and agr-group II (81.2%). The 17 isolates of MSSA carried agr-group I (17.6%), agr-group II (41.2%) or agr group III (29.4%), and 11.8% were non-typable. Figure 3 agr typing among hVISA, MRSA and MSSA isolates. selleck chemicals biofilm Determination of biofilm production Quantitative determination of biofilm formation showed a strong biofilm production in 6 of 24 isolates (25%) STAT inhibitor of hVISA, 9 of 16 isolates
of MRSA (55.5%) and 5 of 17 MSSA isolates (29%). There was no relation between biofilm production and agr group. Discussion Molecular assessment of hVISA isolates indicated a number of PFGE groups, with no substantive evidence of clonal dissemination. Isolates that appeared to be clonal were generally not epidemiologically linked by department or by time. Although the molecular epidemiology of the MRSA isolates in hospitals in Israel has not been explored yet, the high diversity among MRSA isolates in our study is remarkable. In previous reports, VISA and hVISA strains described in Europe belonged to Cyclooxygenase (COX) a restricted range of epidemic multidrug-resistant MRSA strains [4–8], a worrisome finding that highlighted the potential of MRSA strains with reduced susceptibility to vancomycin
to become widespread. However, in our study, genetic lineage was not demonstrated between the hVISA and MRSA isolates. All hVISA isolates had a similar resistance profile to multiple antimicrobial agents, including aminoglycosides and fluoroquinolones. This association between hVISA and a multiresistance phenotype was reported previously [19]. The majority of hVISA and MRSA isolates in the current study harbored SCCmec type I or II, consistent with nosocomial acquisition. However, 25% and 31% of hVISA and MRSA isolates, respectively, carried the SCCmec types IV or V that are related to community acquisition [13, 14]; none of these patients acquired the infection in a community setting, and the antibiotic susceptibility of isolates was compatible with nosocomial acquisition. Furthermore, the PVL gene was found in only one hVISA isolate. Our study reasserted that hVISA, as well as nosocomial acquired MRSA, may carry the so-called community acquired SCCmec types IV and V. It is possible that these clones originated in the community and were introduced by patients who were hospitalized.
No related posts.